Key result
Simvastatin linked to ~34% increased thigh arterial compliance in CAD patients, with no calf effect.
Why the study?
Does simvastatin 40 mg/day improve arterial compliance in patients with proven CAD?
Does simvastatin 40 mg/day improve arterial compliance in patients with proven CAD?
Simvastatin therapy improves arterial compliance in the thigh, suggesting a role for smooth muscle tone modulation by statins in high-risk patients.
Case report precludes practice change; hypothesis-generating for regional statin effects on arterial compliance in CAD.
Reduced arterial compliance is associated with arteriosclerosis. In some arteries, this is due in part to abnormal vascular tone, which can be altered by low-density lipoprotein (LDL) cholesterol reduction and statin therapy. We tested the effectiveness of statin therapy in improving arterial compliance in patients with manifest coronary disease (CAD) and/or diabetes. Simvastatin (40 mg/day) was administered to 10 patients with proven CAD for 4 months. As measured by air plethysmography, compliance of the arterial segments in the thigh improved in every patient after 2 months, increasing by 34% by the fourth month. Compliance at the calf was not affected. These results suggest that compliance in the thigh is controlled by smooth muscle tone. Compliance measurements in the thigh and calf may be a useful measurement in evaluating high-risk patients and monitoring cholesterol-lowering therapy.
No takes yet. Share an insight, caveat, or question.
Saliashvili et al. (2004) studied manifest coronary disease (CAD) and/or diabetes (n=10). Simvastatin was evaluated on compliance of the arterial segments in the thigh and calf (34% increase). Simvastatin (40 mg/day) improved arterial compliance in the thigh by 34% after 4 months in patients with proven coronary artery disease, while compliance at the calf was not affected.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: